References

1. http://www.breastcancer.org/symptoms/understand_bc/statistics.

accessed 20 Feb 2017

2. Kopans DB. Beyond randomized controlled trials. Cancer. 2002;94(2):580-

1.

3. Surveillance, Epidemiology, and End Results (SEER) Program

(www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated

With State, Total U.S. (1969-2014) <Katrina/Rita Population Adjustment>,

National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance

Systems Branch, released December 2016. Underlying mortality data provided

by NCHS (www.cdc.gov/nchs).

4. Hellquist BN, Duffy SW, Abdsaleh S, Björneld L, Bordás P, Tabár L, et al.

Effectiveness of population-based service screening with mammography for

women ages 40 to 49 years: evaluation of the Swedish Mammography Screening

in Young Women (SCRY) cohort. Cancer. 2010;117(4):714-22.

5. Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MMA. Influence

of tumour stage at breast cancer detection on survival in modern times:

population based study in 173 797 patients. BMJ. 2015:h4901.

6. Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O,

et al. Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US

Breast Cancer Mortality. JNCI Journal of the National Cancer Institute.

2014;106(11):dju289-dju.

7. de Gelder R, Heijnsdijk EAM, Fracheboud J, Draisma G, de Koning HJ.

The effects of population-based mammography screening starting between age

40 and 50 in the presence of adjuvant systemic therapy. International Journal of

Cancer. 2014;137(1):165-72.

8. Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticciolo D, et

al. Breast cancer screening with imaging: recommendations from the Society of

Breast Imaging and the ACR on the use of mammography, breast MRI, breast

ultrasound, and other technologies for the detection of clinically occult breast

cancer. J Am Coll Radiol. 2010;7(1):18-27.

9. https://ngc.gov/help-and-about/summaries/inclusion-criteria accessed 05

May 2017

10. Shapiro S. Evaluation of periodic breast cancer screening with

mammography. Methodology and early observations. JAMA: The Journal of the

American Medical Association. 1966;195(9):731-8.

11. Shapiro S. Evidence on screening for breast cancer from a randomized

trial. Cancer. 1977;39(6):2772-82.

12. Tabár L, Gad A, Holmberg LH, Ljungquist U, Fagerberg CJG, Baldetorp L,

et al. Reduction in mortality from breast cancer after mass screening with

mammography. The Lancet. 1985;325(8433):829-32.

13. Hendrick RE, Smith RA, Rutledge JH, Smart CR. Benefit of Screening

Mammography in Women Aged 40-49: A New Meta-Analysis of Randomized

Controlled Trials. JNCI Monographs. 1997;1997(22):87-92.

14. Nyström L, Wall S, Rutqvist LE, Lindgren A, Lindqvist M, Rydén S, et al.

Breast cancer screening with mammography: overview of Swedish randomised

trials. The Lancet. 1993;341(8851):973-8.

15. Larsson L-G, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabár L, et

al. Updated Overview of the Swedish Randomized Trials on Breast Cancer

Screening With Mammography: Age Group 40-49 at Randomization. JNCI

Monographs. 1997;1997(22):57-61.

16. Tabár L, Vitak B, Chen TH-H, Yen AM-F, Cohen A, Tot T, et al. Swedish

Two-County Trial: Impact of Mammographic Screening on Breast Cancer

Mortality during 3 Decades. Radiology. 2011;260(3):658-63.

17. Duffy SW, Tabar L, Smith RA. The Mammographic Screening Trials:

Commentary on the Recent Work by Olsen and Gotzsche. CA: A Cancer Journal

for Clinicians. 2002;52(2):68-71.

18. Smith RA, Duffy SW, Gabe R, Tabar L, Yen AMF, Chen THH. The

randomized trials of breast cancer screening: what have we learned? Radiologic

Clinics of North America. 2004;42(5):793-806.

19. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the

International Workshop on Screening for Breast Cancer. JNCI Journal of the

National Cancer Institute. 1993;85(20):1644-56.

20. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of

mammographic screening from age 40 years on breast cancer mortality in the

UK Age trial at 17 years' follow-up: a randomised controlled trial. The Lancet

Oncology. 2015;16(9):1123-32.

21. Bjurstam NG, Björneld LM, Duffy SW. Updated results of the Gothenburg

Trial of Mammographic Screening. Cancer. 2016;122(12):1832-5.

22. Tabár L, Yen AM-F, Wu WY-Y, Chen SL-S, Chiu SY-H, Fann JC-Y, et al.

Insights from the Breast Cancer Screening Trials: How Screening Affects the

Natural History of Breast Cancer and Implications for Evaluating Service

Screening Programs. The Breast Journal. 2014;21(1):13-20.

23. Feig SA. Screening mammography benefit controversies: sorting the

evidence. Radiol Clin North Am. 2014;52(3):455-80.

24. Alexander FE, Anderson TJ, Brown HK, Forrest APM, Hepburn W,

Kirkpatrick AE, et al. 14 years of follow-up from the Edinburgh randomised trial of

breast-cancer screening. The Lancet. 1999;353(9168):1903-8.

25. Baines CJ, Miller AB, Kopans DB, Moskowitz M, Sanders DE, Sickles EA,

et al. Canadian National Breast Screening Study: assessment of technical quality

by external review. American Journal of Roentgenology. 1990;155(4):743-7.

26. Kopans DB. The Canadian Screening Program: A Different Perspective.

American Journal of Roentgenology. 1990;155(4):748-9.

27. Boyd NF, Jong RA, Yaffe MJ, Tritchler D, Lockwood G, Zylak CJ. A critical

appraisal of the Canadian National Breast Cancer Screening Study. Radiology.

1993;189(3):661-3.

28. Kopans DB, Feig SA. The Canadian National Breast Screening Study: a

critical review. American Journal of Roentgenology. 1993;161(4):755-60.

29. Kopans DB. An open letter to panels that are deciding guidelines for

breast cancer screening. Breast Cancer Research and Treatment.

2015;151(1):19-25.

30. Bailar JC, 3rd, MacMahon B. Randomization in the Canadian National

Breast Screening Study: a review for evidence of subversion. CMAJ.

1997;156(2):193-9.

31. Tarone RE. The excess of patients with advanced breast cancer in young

women screened with mammography in the Canadian National Breast Screening

Study. Cancer. 1995;75(4):997-1003.

32. Tabar L, Duffy SW, Yen MF, Warwick J, Vitak B, Chen HH, et al. All-cause

mortality among breast cancer patients in a screening trial: support for breast

cancer mortality as an end point. Journal of Medical Screening. 2002;9(4):159-

62.

33. Fletcher SW. Breast Cancer Screening Among Women in Their Forties:

An Overview of the Issues. JNCI Monographs. 1997;1997(22):5-9.

34. Koning HJd, Boer R, Warmerdam PG, Beemsterboer PMM, van PJdM.

Quantitative Interpretation of Age-Specific Mortality Reductions From the

Swedish Breast Cancer-Screening Trials. JNCI Journal of the National Cancer

Institute. 1995;87(16):1217-23.

35. Kopans DB. Informed decision making: age of 50 is arbitrary and has no

demonstrated influence on breast cancer screening in women. AJR Am J

Roentgenol. 2005;185(1):177-82.

36. Broeders M, Moss S, Nyström L, Njor S, Jonsson H, Paap E, et al. The

Impact of Mammographic Screening on Breast Cancer Mortality in Europe: A

Review of Observational Studies. Journal of Medical Screening.

2012;19(1_suppl):14-25.

37. Nickson C, Mason KE, English DR, Kavanagh AM. Mammographic

Screening and Breast Cancer Mortality: A Case-Control Study and Meta-

analysis. Cancer Epidemiology Biomarkers & Prevention. 2012;21(9):1479-88.

38. Coldman A, Phillips N, Wilson C, Decker K, Chiarelli AM, Brisson J, et al.

Pan-Canadian Study of Mammography Screening and Mortality from Breast

Cancer. JNCI Journal of the National Cancer Institute. 2014;106(11):dju261-dju.

39. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G,

et al. Effects of mammography screening under different screening schedules:

model estimates of potential benefits and harms. Ann Intern Med.

2009;151(10):738-47.

40. Mandelblatt JS CK dKH, Miglioretti DL, Schecter CS, Stout N. Model

Report: Collaborative Modeling of U.S. Breast Cancer Screening Strategies. . In:

Force USPST, editor. Rockville, MD: AHRQ Publication No. 14-05201 EF-4. ;

2015.

41. Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL,

Krapcho M, et al. Collaborative Modeling of the Benefits and Harms Associated

With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med.

2016;164(4):215-25.

42. Screening for Breast Cancer: U.S. Preventive Services Task Force

Recommendation Statement. Annals of Internal Medicine. 2009;151(10):716.

43. Siu AL. Screening for Breast Cancer: U.S. Preventive Services Task

Force Recommendation Statement. Annals of Internal Medicine.

2016;164(4):279.

44. Hendrick RE, Helvie MA. United States Preventive Services Task Force

Screening Mammography Recommendations: Science Ignored. American

Journal of Roentgenology. 2011;196(2):W112-W6.

45. Hendrick RE, Helvie MA. Mammography Screening: A New Estimate of

Number Needed to Screen to Prevent One Breast Cancer Death. American

Journal of Roentgenology. 2012;198(3):723-8.

46. Arleo EK, Hendrick RE, Helvie MA, Sickles EA. Comparison of

recommendations for screening mammography using CISNET models. . Cancer.

2017;in press.

47. Shulman LN, Willett W, Sievers A, Knaul FM. Breast Cancer in Developing

Countries: Opportunities for Improved Survival. Journal of Oncology.

2010;2010:1-6.

48. Helvie MA, Chang JT, Hendrick RE, Banerjee M. Reduction in late-stage

breast cancer incidence in the mammography era: Implications for overdiagnosis

of invasive cancer. Cancer. 2014;120(17):2649-56.

49. Chu KC, Smart CR, Tarone RE. Analysis of Breast Cancer Mortality and

Stage Distribution by Age for the Health Insurance Plan Clinical Trial. JNCI

Journal of the National Cancer Institute. 1988;80(14):1125-32.

50. Elkin EB, Hudis C, Begg CB, Schrag D. The effect of changes in tumor

size on breast carcinoma survival in the U.S.: 1975-1999. Cancer.

2005;104(6):1149-57.

51. Narod SA. Tumour size predicts long-term survival among women with

lymph node-positive breast cancer. Curr Oncol. 2012;19(5):249-53.

52. Barth RJ, Gibson GR, Carney PA, Mott LA, Becher RD, Poplack SP.

Detection of Breast Cancer on Screening Mammography Allows Patients to Be

Treated with Less-Toxic Therapy. American Journal of Roentgenology.

2005;184(1):324-9.

53. Coldman AJ, Phillips N, Speers C. A retrospective study of the effect of

participation in screening mammography on the use of chemotherapy and breast

conserving surgery. International Journal of Cancer. 2007;120(10):2185-90.

54. Malmgren JA, Parikh J, Atwood MK, Kaplan HG. Impact of Mammography

Detection on the Course of Breast Cancer in Women Aged 40–49 Years.

Radiology. 2012;262(3):797-806.

55. Malmgren JA, Parikh J, Atwood MK, Kaplan HG. Improved Prognosis of

Women Aged 75 and Older with Mammography-detected Breast Cancer.

Radiology. 2014;273(3):686-94.

56. Spillane AJ, Kennedy CW, Gillett DJ, Carmalt HL, Janu NC, Rickard MT,

et al. Screen-detected breast cancer compared to symptomatic presentation: An

analysis of surgical treatment and end-points of effective mammographic

screening. ANZ Journal of Surgery. 2001;71(7):398-402.

57. Zorzi M, Puliti D, Vettorazzi M, De Lisi V, Falcini F, Federico M, et al.

Mastectomy rates are decreasing in the era of service screening: a population-

based study in Italy (1997–2001). British Journal of Cancer. 2006;95(9):1265-8.

58. Geiger AM. A Population-Based Study of Bilateral Prophylactic

Mastectomy Efficacy in Women at Elevated Risk for Breast Cancer in Community

Practices. Archives of Internal Medicine. 2005;165(5):516.

59. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et

al. Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History

of Breast Cancer. New England Journal of Medicine. 1999;340(2):77-84.

60. Moyer VA. Medications for Risk Reduction of Primary Breast Cancer in

Women: U.S. Preventive Services Task Force Recommendation Statement.

Annals of Internal Medicine. 2013.

61. Nelson HD, Smith MEB, Griffin JC, Fu R. Use of Medications to Reduce

Risk for Primary Breast Cancer: A Systematic Review for the U.S. Preventive

Services Task Force. Annals of Internal Medicine. 2013;158(8):604.

62. Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med.

2016;375(3):209-19.

63. Rosenberg RD, Yankaskas BC, Abraham LA, Sickles EA, Lehman CD,

Geller BM, et al. Performance Benchmarks for Screening Mammography.

Radiology. 2006;241(1):55-66.

64. Lee CS, Bhargavan-Chatfield M, Burnside ES, Nagy P, Sickles EA. The

National Mammography Database: Preliminary Data. American Journal of

Roentgenology. 2016;206(4):883-90.

65. Lehman CD, Arao RF, Sprague BL, Lee JM, Buist DSM, Kerlikowske K, et

al. National Performance Benchmarks for Modern Screening Digital

Mammography: Update from the Breast Cancer Surveillance Consortium.

Radiology. 2017;283(1):49-58.

66. Lee CS, Sengupta D, Bhargavan-Chatfield M, Sickles EA, Burnside ES,

Zuley ML. Association of Patient Age With Outcomes of Current-Era, Large-

Scale Screening Mammography: Analysis of Data From the National

Mammography Database. JAMA Oncol. 2017.

67. Grabler P, Sighoko D, Wang L, Allgood K, Ansell D. Recall and Cancer

Detection Rates for Screening Mammography: Finding the Sweet Spot. AJR Am

J Roentgenol. 2017;208(1):208-13.

68. Blanchard K, Colbert JA, Kopans DB, Moore R, Halpern EF, Hughes KS,

et al. Long-term risk of false-positive screening results and subsequent biopsy as

a function of mammography use. Radiology. 2006;240(2):335-42.

69. Gram IT, Lund E, Slenker SE. Quality of life following a false positive

mammogram. British Journal of Cancer. 1990;62(6):1018-22.

70. Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF.

Psychological and behavioral implications of abnormal mammograms. Ann Intern

Med. 1991;114(8):657-61.

71. Sutton S, Saidi G, Bickler G, Hunter J. Does routine screening for breast

cancer raise anxiety? Results from a three wave prospective study in England.

Journal of Epidemiology & Community Health. 1995;49(4):413-8.

72. Scaf-Klomp W, Sanderman R, van de Wiel HB, Otter R, van den Heuvel

WJ. Distressed or relieved? Psychological side effects of breast cancer

screening in The Netherlands. Journal of Epidemiology & Community Health.

1997;51(6):705-10.

73. Gilbert FJ, Cordiner CM, Affleck IR, Hood DB, Mathieson D, Walker LG.

Breast screening: the psychological sequelae of false- positive recall in women

with and without a family history of breast cancer. European Journal of Cancer.

1998;34(13):2010-4.

74. Meystre-Agustoni G, Paccaud F, Jeannin A, Dubois-Arber F. Anxiety in a

cohort of Swiss women participating in a mammographic screening programme.

Journal of Medical Screening. 2001;8(4):213-9.

75. Mainiero MB, Schepps B, Clements NC, Bird CE. Mammography-related

anxiety: effect of preprocedural patient education. Women's Health Issues.

2001;11(2):110-5.

76. Lampic C, Thurfjell E, Bergh J, Sjödén PO. Short- and long-term anxiety

and depression in women recalled after breast cancer screening. European

Journal of Cancer. 2001;37(4):463-9.

77. Heckman BD, Fisher EB, Monsees B, Merbaum M, Ristvedt S, Bishop C.

Coping and Anxiety in Women Recalled for Additional Diagnostic Procedures

Following an Abnormal Screening Mammogram. Health Psychology.

2004;23(1):42-8.

78. Barton MB, Morley DS, Moore S, Allen JD, Kleinman KP, Emmons KM, et

al. Decreasing Women's Anxieties After Abnormal Mammograms: A Controlled

Trial. JNCI Journal of the National Cancer Institute. 2004;96(7):529-38.

79. Yasunaga H, Ide H, Imamura T, Ohe K. Women’s Anxieties Caused by

False Positives in Mammography Screening: A Contingent Valuation Survey.

Breast Cancer Research and Treatment. 2006;101(1):59-64.

80. Aro AR, Pilvikki Absetz S, van Elderen TM, van der Ploeg E, van der

Kamp LJT. False-positive findings in mammography screening induces short-

term distress — breast cancer-specific concern prevails longer. European

Journal of Cancer. 2000;36(9):1089-97.

81. Haas J, Kaplan C, McMillan A, Esserman LJ. Does Timely Assessment

Affect the Anxiety Associated with an Abnormal Mammogram Result? Journal of

Women's Health & Gender-Based Medicine. 2001;10(6):599-605.

82. Brett J, Austoker J. Women who are recalled for further investigation for

breast screening: psychological consequences 3 years after recall and factors

affecting re-attendance. Journal of Public Health. 2001;23(4):292-300.

83. Lampic C, Thurfjell E, Sjödén PO. The influence of a false-positive

mammogram on a woman's subsequent behaviour for detecting breast cancer.

European Journal of Cancer. 2003;39(12):1730-7.

84. Tosteson ANA, Fryback DG, Hammond CS, Hanna LG, Grove MR, Brown

M, et al. Consequences of False-Positive Screening Mammograms. JAMA

Internal Medicine. 2014;174(6):954.

85. Chiarelli AM, Muradali D, Blackmore KM, Smith CR, Mirea L, Majpruz V,

et al. Evaluating wait times from screening to breast cancer diagnosis among

women undergoing organised assessment vs usual care. British Journal of

Cancer. 2017.

86. Hislop TG, Harris SR, Jackson J, Thorne SE, Rousseau EJ, Coldman AJ,

et al. Satisfaction and Anxiety for Women During Investigation of an Abnormal

Screening Mammogram. Breast Cancer Research and Treatment.

2002;76(3):245-54.

87. Ganott MA, Sumkin JH, King JL, Klym AH, Catullo VJ, Cohen CS, et al.

Screening Mammography: Do Women Prefer a Higher Recall Rate Given the

Possibility of Earlier Detection of Cancer? Radiology. 2006;238(3):793-800.

88. Pencina MJ, Navar-Boggan AM, D'Agostino RB, Williams K, Neely B,

Sniderman AD, et al. Application of New Cholesterol Guidelines to a Population-

Based Sample. New England Journal of Medicine. 2014;370(15):1422-31.

89. Puliti D, Duffy SW, Miccinesi G, De Koning H, Lynge E, Zappa M, et al.

Overdiagnosis in Mammographic Screening for Breast Cancer in Europe: A

Literature Review. Journal of Medical Screening. 2012;19(1_suppl):42-56.

90. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox

M. The benefits and harms of breast cancer screening: an independent review.

British Journal of Cancer. 2013;108(11):2205-40.

91. Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS, Shih Y-

CT, et al. Breast Cancer Screening for Women at Average Risk. JAMA.

2015;314(15):1599.

92. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-

diagnosis of breast cancer 15 years after end of Malmo mammographic

screening trial: follow-up study. BMJ. 2006;332(7543):689-92.

93. Gunsoy NB, Garcia-Closas M, Moss SM. Modelling the overdiagnosis of

breast cancer due to mammography screening in women aged 40 to 49 in the

United Kingdom. Breast Cancer Research. 2012;14(6):R152.

94. Hellquist BN, Duffy SW, Nyström L, Jonsson H. Overdiagnosis in the

population-based service screening programme with mammography for women

aged 40 to 49 years in Sweden. Journal of Medical Screening. 2012;19(1):14-9.

95. Bleyer A, Welch HG. Effect of Three Decades of Screening

Mammography on Breast-Cancer Incidence. New England Journal of Medicine.

2012;367(21):1998-2005.

96. Welch HG, Prorok PC, O’Malley AJ, Kramer BS. Breast-Cancer Tumor

Size, Overdiagnosis, and Mammography Screening Effectiveness. New England

Journal of Medicine. 2016;375(15):1438-47.

97. Kopans DB. Arguments Against Mammography Screening Continue to be

Based on Faulty Science. The Oncologist. 2014;19(2):107-12.

98. Duffy SW, Dibden A, Michalopoulos D, Offman J, Parmar D, Jenkins J, et

al. Screen detection of ductal carcinoma in situ and subsequent incidence of

invasive interval breast cancers: a retrospective population-based study. The

Lancet Oncology. 2016;17(1):109-14.

99. Puliti D, Bucchi L, Mancini S, Paci E, Baracco S, Campari C, et al.

Advanced breast cancer rates in the epoch of service screening: The 400,000

women cohort study from Italy. European Journal of Cancer. 2017;75:109-16.

100. Garfinkel L, Boring CC, Heath CW. Changing trends: An overview of

breast cancer incidence and mortality. Cancer. 1994;74(S1):222-7.

101. Bennett RL, Sellars SJ, Moss SM. Interval cancers in the NHS breast

cancer screening programme in England, Wales and Northern Ireland. British

Journal of Cancer. 2011;104(4):571-7.

102. Nederend J, Duijm LEM, Voogd AC, Groenewoud JH, Jansen FH,

Louwman MWJ. Trends in incidence and detection of advanced breast cancer at

biennial screening mammography in The Netherlands: a population based study.

Breast Cancer Research. 2012;14(1).

103. Gilliland FD. Biologic Characteristics of Interval and Screen-Detected

Breast Cancers. Journal of the National Cancer Institute. 2000;92(9):743-9.

104. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney

EA, et al. Breast Tumor Characteristics as Predictors of Mammographic

Detection: Comparison of Interval- and Screen-Detected Cancers. JNCI Journal

of the National Cancer Institute. 1999;91(23):2020-8.

105. Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C,

Rueda A, et al. Aggressiveness features and outcomes of true interval cancers.

European Journal of Cancer Prevention. 2013;22(1):21-8.

106. Strand F, Humphreys K, Cheddad A, Törnberg S, Azavedo E, Shepherd J,

et al. Novel mammographic image features differentiate between interval and

screen-detected breast cancer: a case-case study. Breast Cancer Research.

2016;18(1).

107. Henderson LM, O'Meara ES, Braithwaite D, Onega T. Performance of

digital screening mammography among older women in the United States.

Cancer. 2014;121(9):1379-86.

108. Vyas A, Madhavan S, Sambamoorthi U. Association between persistence

with mammography screening and stage at diagnosis among elderly women

diagnosed with breast cancer. Breast Cancer Research and Treatment.

2014;148(3):645-54.

109. Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, et

al. Mammography Before Diagnosis Among Women Age 80 Years and Older

With Breast Cancer. Journal of Clinical Oncology. 2008;26(15):2482-8.

110. McCarthy EP, Burns RB, Freund KM, Ash AS, Shwartz M, Marwill SL, et

al. Mammography Use, Breast Cancer Stage at Diagnosis, and Survival Among

Older Women. Journal of the American Geriatrics Society. 2000;48(10):1226-33.

111. Vacek PM, Skelly JM. A Prospective Study of the Use and Effects of

Screening Mammography in Women Aged 70 and Older. Journal of the

American Geriatrics Society. 2014;63(1):1-7.

112. McPherson CP, Swenson KK, Lee MW. The Effects of Mammographic

Detection and Comorbidity on the Survival of Older Women with Breast Cancer.

Journal of the American Geriatrics Society. 2002;50(6):1061-8.

113. Dijck JV, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et

al. Breast-cancer mortality in a non-randomized trial on mammographic

screening in women over age 65. International journal of cancer. 1997;70(2):164-

8.

114. Lee SJ, Boscardin WJ, Stijacic-Cenzer I, Conell-Price J, O'Brien S, Walter

LC. Time lag to benefit after screening for breast and colorectal cancer: meta-

analysis of survival data from the United States, Sweden, United Kingdom, and

Denmark. BMJ. 2012;346(jan08 12):e8441-e.

115. Mainiero MB, Lourenco A, Mahoney MC, Newell MS, Bailey L, Barke LD,

et al. ACR Appropriateness Criteria Breast Cancer Screening. Journal of the

American College of Radiology. 2016;13(11):R45-R9.

116. Bernardi D, Caumo F, Macaskill P, Ciatto S, Pellegrini M, Brunelli S, et al.

Effect of integrating 3D-mammography (digital breast tomosynthesis) with 2D-

mammography on radiologists’ true-positive and false-positive detection in a

population breast screening trial. European Journal of Cancer. 2014;50(7):1232-

8.

117. Bernardi D, Ciatto S, Pellegrini M, Anesi V, Burlon S, Cauli E, et al.

Application of breast tomosynthesis in screening: incremental effect on

mammography acquisition and reading time. The British Journal of Radiology.

2012;85(1020):e1174-e8.

118. Caumo F, Bernardi D, Ciatto S, Macaskill P, Pellegrini M, Brunelli S, et al.

Incremental effect from integrating 3D-mammography (tomosynthesis) with 2D-

mammography: Increased breast cancer detection evident for screening centres

in a population-based trial. The Breast. 2014;23(1):76-80.

119. Friedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM,

Greenberg JS, et al. Breast Cancer Screening Using Tomosynthesis in

Combination With Digital Mammography. JAMA. 2014;311(24):2499.

120. Greenberg JS, Javitt MC, Katzen J, Michael S, Holland AE. Clinical

Performance Metrics of 3D Digital Breast Tomosynthesis Compared With 2D

Digital Mammography for Breast Cancer Screening in Community Practice.

American Journal of Roentgenology. 2014;203(3):687-93.

121. Houssami N, Macaskill P, Bernardi D, Caumo F, Pellegrini M, Brunelli S,

et al. Breast screening using 2D-mammography or integrating digital breast

tomosynthesis (3D-mammography) for single-reading or double-reading –

Evidence to guide future screening strategies. European Journal of Cancer.

2014;50(10):1799-807.

122. Lei J, Yang P, Zhang L, Wang Y, Yang K. Diagnostic accuracy of digital

breast tomosynthesis versus digital mammography for benign and malignant

lesions in breasts: a meta-analysis. European Radiology. 2013;24(3):595-602.

123. McCarthy AM, Kontos D, Synnestvedt M, Tan KS, Heitjan DF, Schnall M,

et al. Screening Outcomes Following Implementation of Digital Breast

Tomosynthesis in a General-Population Screening Program. JNCI Journal of the

National Cancer Institute. 2014;106(11):dju316-dju.

124. Rafferty EA, Park JM, Philpotts LE, Poplack SP, Sumkin JH, Halpern EF,

et al. Assessing Radiologist Performance Using Combined Digital Mammography

and Breast Tomosynthesis Compared with Digital Mammography Alone: Results

of a Multicenter, Multireader Trial. Radiology. 2013;266(1):104-13.

125. Rafferty EA, Park JM, Philpotts LE, Poplack SP, Sumkin JH, Halpern EF,

et al. Diagnostic Accuracy and Recall Rates for Digital Mammography and Digital

Mammography Combined With One-View and Two-View Tomosynthesis: Results

of an Enriched Reader Study. American Journal of Roentgenology.

2014;202(2):273-81.

126. Rose SL, Tidwell AL, Ice MF, Nordmann AS, Sexton R, Song R. A Reader

Study Comparing Prospective Tomosynthesis Interpretations with Retrospective

Readings of the Corresponding FFDM Examinations. Academic Radiology.

2014;21(9):1204-10.

127. Skaane P, Bandos AI, Gullien R, Eben EB, Ekseth U, Haakenaasen U, et

al. Prospective trial comparing full-field digital mammography (FFDM) versus

combined FFDM and tomosynthesis in a population-based screening programme

using independent double reading with arbitration. European Radiology.

2013;23(8):2061-71.

128. Skaane P, Bandos AI, Gullien R, Eben EB, Ekseth U, Haakenaasen U, et

al. Comparison of Digital Mammography Alone and Digital Mammography Plus

Tomosynthesis in a Population-based Screening Program. Radiology.

2013;267(1):47-56.

129. Svahn TM, Chakraborty DP, Ikeda D, Zackrisson S, Do Y, Mattsson S, et

al. Breast tomosynthesis and digital mammography: a comparison of diagnostic

accuracy. The British Journal of Radiology. 2012;85(1019):e1074-e82.

130. Takamoto Y, Tsunoda H, Kikuchi M, Hayashi N, Honda S, Koyama T, et

al. Role of Breast Tomosynthesis in Diagnosis of Breast Cancer for Japanese

Women. Asian Pacific Journal of Cancer Prevention. 2013;14(5):3037-40.

131. Ciatto S, Houssami N, Bernardi D, Caumo F, Pellegrini M, Brunelli S, et al.

Integration of 3D digital mammography with tomosynthesis for population breast-

cancer screening (STORM): a prospective comparison study. The Lancet

Oncology. 2013;14(7):583-9.

132. Durand MA, Haas BM, Yao X, Geisel JL, Raghu M, Hooley RJ, et al. Early

Clinical Experience with Digital Breast Tomosynthesis for Screening

Mammography. Radiology. 2015;274(1):85-92.

133. Lourenco AP, Barry-Brooks M, Baird GL, Tuttle A, Mainiero MB. Changes

in Recall Type and Patient Treatment Following Implementation of Screening

Digital Breast Tomosynthesis. Radiology. 2015;274(2):337-42.

134. Rose SL, Tidwell AL, Bujnoch LJ, Kushwaha AC, Nordmann AS, Sexton

R. Implementation of Breast Tomosynthesis in a Routine Screening Practice: An

Observational Study. American Journal of Roentgenology. 2013;200(6):1401-8.

135. Haas BM, Kalra V, Geisel J, Raghu M, Durand M, Philpotts LE.

Comparison of Tomosynthesis Plus Digital Mammography and Digital

Mammography Alone for Breast Cancer Screening. Radiology. 2013;269(3):694-

700.

136. ACR Practice Parameter for the Performance of Screening and Diagnostic

Mammography. 2014; Available at:

https://www.acr.org/~/media/3484ca30845348359bad4684779d492d.pdf Reston,

VA: American College of Radiology; 2014 accessed 05 May 2017

137. Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers R-D, Bieling HB.

Abbreviated Breast Magnetic Resonance Imaging (MRI): First Postcontrast

Subtracted Images and Maximum-Intensity Projection—A Novel Approach to

Breast Cancer Screening With MRI. Journal of Clinical Oncology.

2014;32(22):2304-10.

138. Kuhl CK, Strobel K, Bieling H, Leutner C, Schild HH, Schrading S.

Supplemental Breast MR Imaging Screening of Women with Average Risk of

Breast Cancer. Radiology. 2017;283(2):361-70.

139. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bohm-Velez

M, et al. Combined screening with ultrasound and mammography vs

mammography alone in women at elevated risk of breast cancer. JAMA.

2008;299(18):2151-63.

140. Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, et al.

Detection of breast cancer with addition of annual screening ultrasound or a

single screening MRI to mammography in women with elevated breast cancer

risk. JAMA. 2012;307(13):1394-404.

141. Gartlehner G, Thaler KJ, Chapman A, Kaminski A, Berzaczy D, Van

Noord MG, et al. Adjunct ultrasonography for breast cancer screening in women

at average risk: a systematic review. International Journal of Evidence-Based

Healthcare. 2013;11(2):87-93.

142. Giuliano V, Giuliano C. Improved breast cancer detection in asymptomatic

women using 3D-automated breast ultrasound in mammographically dense

breasts. Clinical Imaging. 2013;37(3):480-6.

143. Brem RF, Tabár L, Duffy SW, Inciardi MF, Guingrich JA, Hashimoto BE, et

al. Assessing Improvement in Detection of Breast Cancer with Three-dimensional

Automated Breast US in Women with Dense Breast Tissue: The SomoInsight

Study. Radiology. 2015;274(3):663-73.

144. Hooley RJ, Greenberg KL, Stackhouse RM, Geisel JL, Butler RS,

Philpotts LE. Screening US in Patients with Mammographically Dense Breasts:

Initial Experience with Connecticut Public Act 09-41. Radiology. 2012;265(1):59-

69.

145. Sun Y, Wei W, Yang H-W, Liu J-L. Clinical usefulness of breast-specific

gamma imaging as an adjunct modality to mammography for diagnosis of breast

cancer: a systemic review and meta-analysis. European Journal of Nuclear

Medicine and Molecular Imaging. 2012;40(3):450-63.

146. Kim BS, Moon BI, Cha ES. A comparative study of breast-specific gamma

imaging with the conventional imaging modality in breast cancer patients with

dense breasts. Annals of Nuclear Medicine. 2012;26(10):823-9.

147. Hendrick RE, Tredennick T. Benefit to Radiation Risk of Breast-specific

Gamma Imaging Compared with Mammography in Screening Asymptomatic

Women with Dense Breasts. Radiology. 2016;281(2):583-8.

148. http://www.facingourrisk.org/our-role-and-impact/advocacy/documents/

breast-screening-comparison-chart.pdf 2016

149. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp 2016

150. The American Congress of Obstetricians and Gynecologists. Practice

Bulletin 2014. available at: https://www.acog.org/Resources-And-

Publications/Practice-Bulletins/Committee-on-Practice-Bulletins-

Gynecology/Breast-Cancer-Screening. Accessed June 7, 2017

151. Arleo EK, Monticciolo DL, Monsees B, McGinty G, Sickles EA. Persistent

Untreated Screening-Detected Breast Cancer: An Argument Against Delaying

Screening or Increasing the Interval Between Screenings. J Am Coll Radiol.

2017.